Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

NCT ID: NCT03890302

Last Updated: 2020-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-14
• Study Completion Date: 2020-05-27

Brief Summary

The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical in RA. This study investigates the drug FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2 sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part (Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in both parts will have a short stay in the clinic at the start of the study, then will return for outpatient visits.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cohort A

0.5 mg/kg study drug, or placebo, administered once

Group Type: EXPERIMENTAL

FB704A

Intervention Type: DRUG

Administered by IV infusion

Placebo

Intervention Type: DRUG

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Cohort B

2 mg/kg study drug, or placebo, administered once

Group Type: EXPERIMENTAL

FB704A

Intervention Type: DRUG

Administered by IV infusion

Placebo

Intervention Type: DRUG

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Cohort C

4 mg/kg study drug, or placebo, administered once

Group Type: EXPERIMENTAL

FB704A

Intervention Type: DRUG

Administered by IV infusion

Placebo

Intervention Type: DRUG

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Cohort D

8 mg/kg study drug, or placebo, administered once

Group Type: EXPERIMENTAL

FB704A

Intervention Type: DRUG

Administered by IV infusion

Placebo

Intervention Type: DRUG

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Cohort E

Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).

Group Type: EXPERIMENTAL

FB704A

Intervention Type: DRUG

Administered by IV infusion

Placebo

Intervention Type: DRUG

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Interventions

FB704A

Administered by IV infusion

Intervention Type: DRUG

Placebo

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects must provide written informed consent.
• No significant clinical, cardiac or physical abnormalities (Part 1 of study).
• Diagnosis of Rheumatoid Arthritis as defined by 2010 revised American College of Rheumatology (ACR) more than 3 months prior to start of study (Part 2 of study).
• If using oral corticosteroids (prednisone ≤ 10mg or equivalent) and/or NSAIDS, subjects must be on stable dose(s) for at least 14 days prior to start of Part 2 of study and dose must be expected to remain stable through end of Part 2 of study.
• Subjects must be being treated with 1 or a combination of disease modifying antirheumatic drugs (DMARDs) methotrexate, leflunomide, sulfasalazine, and/or hydroxychloroquine (but not simultaneous use of leflunomide and methotrexate), at any dose for at least 28 days prior to start of Part 2 of study and on a stable dose(s) for at least 14 days prior to start of Part 2 of study.
• Women of childbearing potential must agree to use one of the accepted contraceptive regimens from at least 30 days prior to first administration of the study medication, during the study, and for at least 60 days after last dose of the study medication.
• Women of non-childbearing potential should be surgically sterile or in a menopausal state (at least 1 year without menses).
• All males must agree to use highly effective contraception and to not donate sperm throughout the study and for 90 days following last dose of study medication.
• Subjects must have a body weight ≥ 50 kg at screening and a body mass index (BMI) of 19.0 to 30.0 kg/m2, inclusive (Part 2 of study).
• Subjects must have not smoked or used any nicotine products for at least 3 months before screening (Part 1 of study).

Exclusion Criteria

• Women who are pregnant or lactating.
• Subject has a past history of, or a history of risk factors for, heart arrhythmias or long QT syndrome.
• Subject has recurrent chronic serious infection, or has had a serious infection within 60 days of start of study.
• Subject has latent or active tuberculosis.
• Subject has received any live attenuated vaccine (e.g. varicella-zoster, oral polio, rabies, flu vaccine) within 3 months of start of study.
• Subject has received any biological drug or blood product within 3 months or 5 half-lives of start of study; or has received any other study drug within 30 days or 5 half-lives of start of study.
• Subject has previously been treated with any biologic, anti-interleukin-6 (anti-IL-6) or interleukin-6 receptor (IL-6) antagonist and/or has previous exposure to the study drug.
• Subjects with a documented history of an autoimmune disease other than rheumatoid arthritis or secondary Sjogren's syndrome.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Oneness Biotech Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Fountain Biopharma Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Kankam, MD

Role: PRINCIPAL_INVESTIGATOR

Altasciences Clinical Kansas, Inc.

Locations

Altasciences Clinical Kansas, Inc.

Overland Park, Kansas, United States

Countries

United States

Related Links

http://www.fda.gov/Safety/Recalls

FDA Safety Alerts and Recalls

Other Identifiers

FB704ACLIS-01-RA

Identifier Type: -

Identifier Source: org_study_id